BRPI0511603A - método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados - Google Patents

método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados

Info

Publication number
BRPI0511603A
BRPI0511603A BRPI0511603-1A BRPI0511603A BRPI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A
Authority
BR
Brazil
Prior art keywords
treatment
disorders
nasps
sulfated polysaccharides
bleeding disorders
Prior art date
Application number
BRPI0511603-1A
Other languages
English (en)
Inventor
Kirk Johnson
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Publication of BRPI0511603A publication Critical patent/BRPI0511603A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731Carrageenans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MéTODO PARA O TRATAMENTO DE DISTúRBIOS DO SANGRAMENTO COM A UTILIZAçãO DE POLISSACARìDEOS SULFATADOS. São revelados para o tratamento de distúrbios do sangramento com a utilização de polissacarídeos sulfatados não anticoagulantes (NASPs) como pró-coagulantes. NASPs podem ser administrados como agentes únicos, ou em combinação com outros, ou com outras medicações (tais como fatores VII, VIII e IX) para promover hemostasia. Em particular, é descrito o uso de NASPS no tratamento de distúrbios do sangramento, incluindo distúrbios da coagulação congênitos, distúrbios da coagulação adquiridos e condições hemorrágicas induzidas por trauma.
BRPI0511603-1A 2004-05-27 2005-05-27 método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados BRPI0511603A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57484504P 2004-05-27 2004-05-27
PCT/US2005/018669 WO2005117912A1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides

Publications (1)

Publication Number Publication Date
BRPI0511603A true BRPI0511603A (pt) 2008-01-02

Family

ID=35462725

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511603-1A BRPI0511603A (pt) 2004-05-27 2005-05-27 método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados

Country Status (16)

Country Link
US (4) US7767654B2 (pt)
EP (2) EP2165711B1 (pt)
JP (2) JP5232470B2 (pt)
CN (2) CN103251647A (pt)
AU (1) AU2005249465B2 (pt)
BR (1) BRPI0511603A (pt)
CA (1) CA2567495C (pt)
CY (1) CY1113705T1 (pt)
DK (1) DK1748781T3 (pt)
ES (2) ES2482105T3 (pt)
HK (2) HK1103624A1 (pt)
PL (1) PL1748781T3 (pt)
PT (1) PT1748781E (pt)
RU (1) RU2347574C2 (pt)
SI (1) SI1748781T1 (pt)
WO (1) WO2005117912A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
ES2482105T3 (es) * 2004-05-27 2014-08-01 Baxter International Inc. Procedimientos de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
US20080107678A1 (en) * 2006-04-27 2008-05-08 Johnson Kirk W Method for treating thrombotic disorders using sulfated polysaccharides
EP3409694A1 (en) * 2007-02-23 2018-12-05 Baxalta GmbH Process methods for fucoidan purification from seaweed extracts
US9956272B2 (en) * 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
CA2731304C (en) * 2008-08-22 2017-06-06 Baxter Healthcare S.A. Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides
CA2746257C (en) * 2008-12-11 2018-01-16 Baxter International Inc. Preparations based on fibrinogen and sulfated polysaccharides
NZ607892A (en) 2008-12-19 2014-11-28 Baxter Int Tfpi inhibitors and methods of use
JP6393453B2 (ja) * 2010-01-14 2018-09-19 バクスアルタ ゲーエムベーハー 出血性障害を治療するための方法及び組成物
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
KR102049254B1 (ko) * 2010-04-20 2019-11-28 옥타파마 아게 약학 단백질을 위한 신규한 안정화제
EP2624859B1 (en) 2010-10-06 2017-03-01 Medimmune Limited Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
WO2013012954A2 (en) * 2011-07-19 2013-01-24 Baxter International Inc. Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
JP6228137B2 (ja) 2012-01-30 2017-11-08 バクスアルタ ゲーエムベーハー 非抗凝固性の硫酸化またはスルホン酸化多糖
EP2809330B1 (en) * 2012-01-30 2019-06-12 Baxalta GmbH Non-anticoagulant sulfated or sulfonated synthetic polymers
NZ629130A (en) 2012-03-21 2016-10-28 Baxalta Inc Tfpi inhibitors and methods of use
RU2472495C1 (ru) * 2012-05-05 2013-01-20 Илья Николаевич Медведев Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
DK2885642T3 (da) * 2012-08-14 2019-07-29 Baxalta GmbH Fremgangsmåder og systemer til screening af sammensætninger omfattende ikke-antikoagulerende sulfaterede polysaccharider
CN103610684B (zh) * 2013-11-07 2016-04-06 苏州大学 糖类在制备治疗血小板数量相关疾病的药物中的应用
JP6225321B1 (ja) 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
BR112020003908B1 (pt) 2016-08-31 2023-01-24 Oji Holdings Corporation Método para produzir um ingrediente farmacêutico ativo incluindo polissulfato de pentosano
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
BR112019025030A2 (pt) 2017-05-31 2020-06-16 Oji Holdings Corporation Preparação umidificante tópica.
AU2018333249B2 (en) 2017-09-12 2023-03-02 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate
MX2020006605A (es) 2017-12-20 2020-09-10 Oji Holdings Corp Polisulfato de pentosano y medicamento que contiene polisulfato de pentosano.
CN108822231A (zh) * 2018-06-29 2018-11-16 桂林理工大学 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法
SE1950885A1 (en) * 2019-07-11 2021-01-12 Faelker Knut Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
JP3094165B2 (ja) * 1990-11-05 2000-10-03 バクスター、ダイアグノスチックス、インコーポレイテッド 抗凝固剤濃度測定方法
JP3714426B2 (ja) 1994-02-01 2005-11-09 株式会社糖鎖工学研究所 フコイダンオリゴ糖組成物含有癌転移抑制剤
JP3605414B2 (ja) * 1995-04-28 2004-12-22 タカラバイオ株式会社 糖化合物
FR2754183A1 (fr) * 1996-10-08 1998-04-10 Lefebvre Jean Marie Composition visqueuse hemostatique, notamment a l'etat de gel
US6426192B1 (en) * 1997-04-25 2002-07-30 Pentapharm Ag Method for the functional detection of disorders in the protein C system
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
KR100727339B1 (ko) * 1999-04-15 2007-06-12 다카라 바이오 가부시키가이샤 치료제
AU2001244602A1 (en) * 2000-03-30 2001-10-15 Ajinomoto Co. Inc. Drugs retained in target tissue over long time
ES2301624T3 (es) * 2001-02-05 2008-07-01 Novo Nordisk Health Care Ag Uso combinado de polipeptidos de factor vii y polipeptidos de factor viii.
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
ES2236420T3 (es) * 2001-10-24 2005-07-16 Takara Bio Inc. Oligosacarido de fucano sulfatado.
JP3941036B2 (ja) * 2001-12-07 2007-07-04 サンスター株式会社 経口投与のためのリポソーム組成物
DE10309368A1 (de) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
IL152030A0 (en) * 2002-09-30 2003-05-29 Nvr Labs Ltd Neural & Vascular Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair
JP2004144580A (ja) * 2002-10-23 2004-05-20 Japan Clinical Laboratories Inc 血液凝固検査方法
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
ES2482105T3 (es) * 2004-05-27 2014-08-01 Baxter International Inc. Procedimientos de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
US20080107678A1 (en) 2006-04-27 2008-05-08 Johnson Kirk W Method for treating thrombotic disorders using sulfated polysaccharides

Also Published As

Publication number Publication date
WO2005117912A1 (en) 2005-12-15
EP1748781B1 (en) 2012-12-19
RU2006146801A (ru) 2008-07-10
EP2165711A1 (en) 2010-03-24
ES2399277T3 (es) 2013-03-27
US20110237512A1 (en) 2011-09-29
CN1984664A (zh) 2007-06-20
AU2005249465A1 (en) 2005-12-15
PT1748781E (pt) 2013-01-22
HK1142276A1 (en) 2010-12-03
US20050282771A1 (en) 2005-12-22
EP2165711B1 (en) 2014-05-21
US20120129777A1 (en) 2012-05-24
ES2482105T3 (es) 2014-08-01
DK1748781T3 (da) 2013-02-11
CY1113705T1 (el) 2016-06-22
JP5232470B2 (ja) 2013-07-10
EP1748781A4 (en) 2008-07-02
EP1748781A1 (en) 2007-02-07
CN1984664B (zh) 2013-07-24
JP2012046551A (ja) 2012-03-08
AU2005249465B2 (en) 2007-12-06
US7829549B2 (en) 2010-11-09
CA2567495A1 (en) 2005-12-15
RU2347574C2 (ru) 2009-02-27
US7767654B2 (en) 2010-08-03
CA2567495C (en) 2014-02-18
HK1103624A1 (en) 2007-12-28
CN103251647A (zh) 2013-08-21
PL1748781T3 (pl) 2013-05-31
SI1748781T1 (sl) 2013-03-29
US8859526B2 (en) 2014-10-14
US8771973B2 (en) 2014-07-08
JP2008500367A (ja) 2008-01-10
US20090269325A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
BRPI0511603A (pt) método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados
Pereira et al. Influence of Aloe vera on water absorption and enzymatic in vitro degradation of alginate hydrogel films
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
MX2009001323A (es) Aposito solido para tratar tejido herido.
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
PH12013501791B1 (en) Uses of dpp-iv inhibitors
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
WO2007007098A3 (en) Promotion of epithelial regeneration
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
WO2007038686A3 (en) Amniotic membrane preparations and purified compositions and methods of use
MX2010003019A (es) Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
EP2497478A3 (en) Oligosaccaride compositions and use thereof in the treatment of infection
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2007098114A3 (en) Clotting and healing compositions containing keratin biomaterials
BR112016009954A2 (pt) terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação
WO2009081408A3 (en) Pulverized fibrin clots and pharmaceutical compositions containing them
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof
BRPI0516134A (pt) neurotoxinas de clostridium para uso na cicatrização de tecidos
Budko et al. Local hemostatic agents and ways of their improvement

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.